






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification ⁶ : C07D 323/00, A61K 31/335 | | A1 | (11) International Publication Number: WO 97/30042 |
| | | | (43) International Publication Date: 21 August 1997 (21.08.97) |
| (21) International Application Number: PCT/JP97/00353 | | (81) Designated States: AU, BR, CA, CN, IL, JP, KR, MX, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). | |
| (22) International Filing Date: 10 February 1997 (10.02.97) | | Published With international search report. With amended claims and statement. | |
| (30) Priority Data: 8/25615 13 February 1996 (13.02.96) JP | | | |
| (71) Applicant (for all designated States except US): GLOBAL ART CO. LTD. [JP/JP]; 2-15, Chuo 2-chome, Yamato-shi, Kanagawa 242 (JP). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): SONE, Hisao [JP/JP]; 11-12, Maimatsubara 3-chome, Higashi-ku, Fukuoka-shi, Fukuoka 813 (JP). SAKAIRI, Masaki [JP/JP]; 25-6-202, Ohi 5-chome, Shinagawa-ku, Tokyo 140 (JP). YOSHIKAWA, Noriko [JP/JP]; 13, Tsurugaoka, Tsurugashima-shi, Saitama 350-02 (JP). ISA, Etsuko [JP/JP]; 6-13-308, Niiza 3-chome, Niiza-shi, Saitama 352 (JP). | | | |
| (74) Agents: ISHIKAWA, Yasuo et al.; Park Shiba Building, 4F, 17-11, Shiba 2-chome, Minato-ku, Tokyo 105 (JP). | | | |

(54) Title: POLYESTER CYCLIC COMPOUNDS, THEIR COMPLEXES AND BONDED BODIES

(57) Abstract

It is provided a polyester cyclic compound represented by formula (1). It is also provided a complex of a polyester cyclic compound represented by formula (1), (3) or (4) and a compound containing an OH group(s). It is still further provided a bonded body of an ester compound and the cyclic compound represented by the formula (1), (3) or (4), or the complex. The above-described compounds demonstrate various pharmacological effects, such as carcinostatic effect and immunological regulation, specifically to a living body. (In the formulae, each "R" is independently H, a C₁-C₅ alkyl group, or a C₁-C₅ alkyl group wherein one or more H is replaced by F, and "n" is an integer of 2 to 9).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

DESCRIPTION

POLYESTER CYCLIC COMPOUNDS, THEIR COMPLEXES AND BONDED BODIES

5 Technical Field :

The present invention relates to a polyester cyclic compound, a complex of the cyclic compound and a compound containing a OH group or groups, and a bonded body of an ester
10 compound and the cyclic compound or the complex, which demonstrate various pharmacological effects, such as carcinostatic effect and immunological regulation, to a living body.

15 Background Art :

Recently, relationship between enteric bacteria and carcinogenesis has been researched progressively. Particularly, it is said that change in intestinal bacterial flora plays a major role in the formation of carcinogens and
20 substances for promoting carcinogenesis and their activation or suppression.

Especially, utility of lactic acid bacteria attracts attention and it is said that immune response of a host may be improved by supplying lactic acid bacteria or products of
25 cultivation thereof, and that lactic acid bacteria may suppress proliferation of intestinal bacteria relating to

production of carcinogens and carcinogenesis-promoting substances to suppress occurrence of tumors.

However, which substance among products of lactic acid bacteria provides such effects has not known yet.

5 Besides, Lactic acid is well known as a main substance produced by lactic acid bacteria. Lactic acid is an usual component in animal's bodies and is produced in muscles. Most of produced lactic acid is utilized as a substrate for TCA cycle or gluconeogenesis in the liver or kidney.

10

Disclosure of Invention :

 The inventors considered such circumstance and made intensive research on the subject, and finally found that
15 specific polyester cyclic compound synthesized from a hydroxy acid such as lactic acid demonstrated various pharmacological effects, such as carcinostatic effect and immunological regulation, specifically to a living body.

 The inventors further made research for improving
20 the effects of the polyester cyclic compound and found that a complex formed by mixing and heating the polyester cyclic compound and a compound containing a OH group or groups(referred as " OH group-containing compound " below) demonstrated various pharmacological effects more
25 specifically to a living body.


Moreover, the inventors found that the polyester

cyclic compound or the complex bonded with an ester compound, such as a phosphoric ester, sulfuric ester or carbonic ester with a low or high molecular weight, to form a bonded body and be further stabilized. The bonded body also
 5 demonstrated various pharmacological effects.


The invention was established based on these discoveries. Namely, it is an object of the invention to provide a novel polyester cyclic compound, its complex and a bonded body of the polyester cyclic compound which
 10 demonstrate various pharmacological effects such as carcinostatic effect and immunological regulation.

To give a solution to the above problems, the invention provides a polyester cyclic compound represented by the following formula (1)

15






20 (in the formula (1), each "R" is independently hydrogen atom, an alkyl group having 1 - 5 carbon atoms, or an alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom, and "n" is an integer of 2 to 9.), or the following formula (2).






(" n " is same as above)

The invention further provides a complex of at least one compound containing a OH group or groups therein and at least one polyester cyclic compound selected from a group consisting of a compound of the following formula (1), a compound of the following formula (3) and a compound of the following formula (4).



(in the formulas, " R " and " n " are same as above)

The invention further provides a bonded body obtained by bonding of at least one ester compound and at least one polyester cyclic compound selected from a group consisting of a compound of the following formula (1), a compound of the following formula (3) and a compound of the following formula (4)



(in the formulas, " R " and " n " are same as above), or by bonding of at least one ester compound and at least one complex of said polyester cyclic compound and a compound containing a OH group or groups therein.

The polyester cyclic compound, complex of the polyester cyclic compound and bonded body demonstrate pharmacological effects, such as carcinostatic effect and immunological regulation specifically to a living body and hardly demonstrate any toxicity. Particularly, the complex demonstrates various pharmacological effects more specifically than the polyester cyclic compound. Moreover, the bonded body, obtained by bonding the polyester cyclic compound or the complex and an ester compound with a low or high molecular weight, also demonstrates various pharmacological effects as described above.

The reason why the pharmacological effects was improved by converting the polyester cyclic compound to the complex may be assumed as follows.

Namely, the complex is obtained from the polyester cyclic compound of the formula (1), (3), or (4) and an OH group-containing compound such as an alcohol, phenol or hydroxy acid compound. Such complex may be readily dissolved into water by the effect of the OH group-containing compound. Therefore, it is assumed that the polyester cyclic compound demonstrating various pharmacological effects is readily absorbed into a living body and further stabilized to improve its effects.

Moreover, the effect of the bonded body of an ester compound and the polyester cyclic compound or its complex may be assumed as follows.

Namely, it is assumed that the bonded body is obtained by the bonding, for example electrostatic bonding of the cyclic compound or its complex with a phosphoric group, sulfuric group or carbonic group of a phosphoric ester, sulfuric ester or carbonic ester with a low or high molecular weight. It is also assumed that the bonded body is stabilized in water by the effect of the thus bonded ester compound to improve the above pharmacological effects.

By the complex or the bonded body of the invention, the polyester cyclic compound may be utilized more effectively. Besides, such complex or bonded body may be applied for utilizing the OH group-containing compound more effectively. That is, when pharmacological effects or the other effects of the OH group-containing compound are to be expected, such OH group-containing compound may be reacted with one of various polyester cyclic compounds to provide a complex, or the complex may be bonded with the ester compound. As a result, the OH group-containing compound may be stabilized during preparing pharmacological compositions, in digestive tracts, and on skin or the like, the absorption efficiency of the OH group-containing compound may be improved in digestive tracts or from skin, and the complex or the bonded body may form micelles with a uniform diameter to promote the efficiency of drug delivery in a living body.


A medical or pharmaceutical composition containing, as its effective component, at least one of the polyester

cyclic compound, or at least one complex of the polyester cyclic compound and an OH group-containing compound, or at least one bonded body obtained by bonding of an ester compound and the polyester cyclic compound or the complex may be applied to medication or prevention of cancer, rheumatism, prostic disease, dementia, chronic hepatitis, autoimmune disease, allergic diseases, menopausal syndrome, menstrual pain or adult diseases such as diabetes and hypertension.

Best Mode for Carrying Out the Invention :

The preferred embodiments of the invention will be described below in detail.

First, the polyester cyclic compound of the formula (1) will be described. In the cyclic compound of the formula (1), repeating units in the formula may be same or different to each other. Number of carbon atoms of " R " may preferably be 1 to 3. The polyester cyclic compound may be obtained by subjecting one compound or mixture of two or more compounds, selected from a group consisting of hydroxy acids (oxyacids) of the following formula (5), to dehydration and polycondensation under heating condition to produce distillate fraction, and purifying it.



(in the formula, " R " is same as above. Number of carbon atoms of " R " is preferably 1 to 3)

The hydroxy acid as a starting material includes, for example, lactic acid, fluorolactic acid, glycollic acid or the like. Besides, a concentration of the hydroxy acid in raw material may preferably be higher to improve operation efficiency.

A temperature for heating the hydroxy acid is normally 100 - 250 °C and preferably be 100 - 200 °C. When the temperature is lower than 100 °C, the dehydration and polycondensation may not take place sufficiently. On the contrary, when the temperature is higher than 250 °C, polycondensation may be overwhelmed by depolymerization, and dimers of the hydroxy acids may occasionally be formed.

Final pressure during the dehydration and polycondensation is normally 30 - 1 mmHg and preferably 10 - 1 mmHg. When the pressure is higher than 30 mmHg, the dehydration and polycondensation may not take place sufficiently. On the contrary, the pressure set below 1 mmHg does not provide further effects and rather results in poor efficiency.

A time period for the dehydration and polycondensation is normally not less than 2 hours and preferably 4 - 10 hours.

The polyester cyclic compound of the formula (1) includes, for example, compounds of the above formula (2).

The polyester cyclic compound of the formula (2) may be obtained by subjecting lactic acid to dehydration and polycondensation under heating condition to produce distillate fraction and purifying it. When synthesizing the
5 compound of the formula (2), practical operations may be carried out, for example, according to the following procedure.

First, lactic acid as a starting material is prepared. Lactic acid may be selected voluntarily from L-, D- and DL-
10 lactic acids, which may be used alone or in combination. Besides, in the viewpoint of operation efficiency, a concentration of lactic acid may preferably be higher.

Lactic acid is then reacted to remove water in a condition of a temperature of not lower than 100 °C and a
15 pressure of 760 mmHg - 300 mmHg for not less than 2 hours. For example, Lactic acid is reacted for 4 to 6 hours in reduced pressures while gradually increasing reaction temperatures from 100 °C to 140 °C and reducing pressures from 760 mmHg to 300 mmHg.

20 Thereafter, lactic acid is subjected to polycondensation to recover distillate fraction, at a temperature of not lower than 100 °C and a pressure of 10 mmHg - 1 mmHg for not less than 2 hours, for example, at 140 °C /10mmHg for 4 - 6 hours.



25 After the reaction is completed, the above distillate fraction is purified.

The purification is accomplished by dissolving the distillate fraction into an organic solvent, which has the ability to dissolve the crystals of the distillate, such as ethyl acetate or chloroform, and by then carrying out partition extraction using an alkali solution such as sodium hydroxide solution and sodium bicarbonate solution.

After the purification, recrystallization using an organic solvent such as diethylether results in the compound of the formula (2).

The compound may be synthesized only from lactic acid without any catalysts and is a polyester cyclic compound comprising an ester bonding of n moles of lactic acid and one mole of demethylized lactic acid.

The compound of the formula (2) specifically includes the compounds having the following structures (6) and (7).



The polyester cyclic compound demonstrates various pharmacological effects such as carcinostatic effect and immunological regulation specifically to a living body and hardly demonstrates any toxicity. Therefore, the compound is particularly effective for medication or prevention of cancer, rheumatism, prostic disease, dementia, chronic hepatitis, autoimmune disease, allergic diseases, menopausal syndrome, menstrual pain or adult diseases such as diabetes and hypertension.

The complex of the polyester cyclic compound provided by the invention will be explained below. The complex of the invention is composed of the OH group-containing compound and the polyester cyclic compound of the formula (1), (3) or (4). Such complex may be obtained, for example, by mixing and heating the OH group-containing compound and the polyester cyclic compound. The complex may be obtained by mixing one or more polyester cyclic compound and one or more OH group-containing compound.

The polyester cyclic compound, as a starting material for the complex, not only includes the compound of the formula (1) and but also includes the compounds of the formulas (3) and (4). The compound of the formula (3) is a glycollide and the compound of the formula (4) is a lactide. These two compounds are known. The polyester cyclic compound may be used alone, or two or more compounds may be used in combination. Moreover, commercial glycollide or

lactide may be used and, when the glycolide or lactide includes optical isomers, each of the isomers may be used.

The OH group-containing compound as the other starting material of the complex includes generally an organic compound or an inorganic compound each containing an OH group. However, an organic compound having an alcoholic hydroxyl group or a phenolic hydroxyl group, or an hydroxy acid may be normally used. The organic compound containing an OH group includes, for example, monovalent or polyvalent alcohols(including primary, secondary and tertiary alcohols) such as methanol, ethanol, 2-butanol, propylene glycol, saccharides ; monovalent or polyvalent phenols such as phenol, cresol, catechol ; hydroxy acids such as glycolic acid, lactic acid, tartaric acid. The OH group-containing compound may be a mixture of two or more compounds selected from the above listed compounds and their salts.

The OH group-containing compound may be newly synthesized, or commercially available. When the compound includes optical isomers, each isomer may be used. when the OH group-containing compound is of crystalline form, the crystal may preferably dissolved into a solvent, which readily dissolves the crystal and does not reacts with the polyester cyclic compound, such as dimethylsulfoxide, to provide solution which is used for the reaction with the cyclic compound.

The polyester cyclic compound and the OH group-

containing compound are prepared, then charged into a reaction container, and heated for a predetermined time period. A temperature for the heating is not less than a room temperature and preferably 50 - 100 °C.

5 A time period for the reaction may be properly determined depending on the properties of the OH group-containing compound and the heating temperature. Generally, the higher the heating temperature, the shorter the reaction time period, and the lower the heating temperature, the longer
10 the reaction time period.

 It is used a reaction container which does not reacts with the polyester cyclic compound and the OH group-containing compound and has a structure not leaking the evaporated OH group-containing compound during heating. For example, a
15 closed glass container or a glass container with a reflux condenser may be used.

 Thereafter, unreacted OH group-containing compound was removed by distillation under a reduced pressure or another method, and the thus obtained product was purified
20 by means of a separating method such as partition extraction or chromatography to obtain the complex of the polyester cyclic compound of the invention.

 The thus purified complex may be confirmed by retention times (referred to as "RT" below) of peaks, which
25 is obtained by concentration gradient elution using water-acetonitrile by means of high performance liquid

chromatography (referred to as "HPLC" below) with a detector of ultraviolet light and visible light using an ODS column. Generally, a saturated alcohol or a saccharide does not provide a UV absorption peak at 210 nm, a phenol, a hydroxy acid and a salt of neutralized hydroxy acid provide UV peaks at characteristic RT's, respectively. However, the complex of the polyester cyclic compound provides a UV peak at an RT different from the RT's of the above compounds.

The thus obtained complex may be readily separated into the polyester cyclic compound and the OH group-containing compound by heating it with water for a long time. Therefore, the complex obtained by the above reaction is considered to be a so called "complex" formed by the polyester cyclic compound and the OH group-containing compound.

The thus obtained complex demonstrates various pharmacological effects such as carcinostatic effect and immunological regulation specific to a living body of human and animals. Moreover, the complex hardly demonstrates any toxicity. Therefore, the complex is particularly effective for medication or prevention of cancer, rheumatism, prostic disease, dementia, chronic hepatitis, autoimmune disease, allergic diseases, menopausal syndrome, menstrual pain or adult diseases such as diabetes and hypertension.

The complex forms micelles by the effect of the OH group-containing compound to be easily dissolved into water when mixed with water. The complex may be more readily bonded

with an ester compound such as a phosphoric ester, a sulfuric ester or a carbonic ester each having a low or high molecular weight. Therefore, it is assumed that the polyester cyclic compound, demonstrating various pharmacological effects, may
5 be easily absorbed into a living body and is more stabilized to improve the effects.

While, when the OH group-containing compound has 4 or more carbon atoms, its solubility to water is generally small. However, when such OH group-containing compound is
10 reacted with the polyester cyclic compound represented by the formula (1) to (4) or the like to form the complex, it forms micelles in water to be readily dissolved into water. Moreover, the stability of the OH group-containing compound itself is improved.

15 Therefore, by forming the complex of the OH group-containing compound and the polyester cyclic compound, the OH group-containing compound may be stabilized during preparing pharmacological compositions, in digestive tracts, or on skin or the like, the absorption efficiency of the OH
20 group-containing compound may be improved in digestive tracts or from skin, and the complex may form micelles with a uniform diameter to promote the efficiency of drug delivery in a living body.

The bonded body may be obtained by bonding the
25 polyester cyclic compound or the complex and an ester compound such as a phosphoric ester, a sulfuric ester or a carbonic

ester each having a low or high molecular weight. Particularly, the ester compound may form a bond more easily with the complex which may be readily dissolved into water. It was difficult to isolate the bonded body, however, its
5 characteristic peak was confirmed by means of HPLC. Moreover, when the ester compound was removed from the bonded body by alkali-neutralization extraction and the thus obtained product was measured by HPLC again, the characteristic peak of the original polyester cyclic compound
10 or the complex was confirmed. From such results, it is assumed that the bonded body is formed by the bonding, for example, electrostatic bonding of the polyester cyclic compound or its complex with a phosphoric group, sulfuric group or carbonic group of the ester compound. By the effect
15 of the thus bonded ester compound, it is assumed that the bonded body becomes more stable in water and therefore the above pharmacological effects was further improved.

Examples :

20

The present invention will be further explained below in detail referring to the following examples.

First, the polyester cyclic compounds of the formulas (1) to (4) are synthesized as shown in examples 1
25 to 8 and explained in detail.

(Example 1)

[The compound of formula (1) wherein " R " is CH₃ :
same as the compound of formula (2)]

200 ml of (L- or DL-) lactic acid was heated in
5 nitrogen flow at 140 °C/300 mmHg for 1 hour to remove distilled
water. Lactic acid was then heated at temperatures which
were gradually increased from 140 °C to 180 °C at 10 mmHg so
that it was dehydrated and polycondensed for 4 hours to produce
distillate.

10 The distillate was dissolved in ethyl acetate and
subjected to partition extraction using saturated aqueous
solution of sodium bicarbonate to obtain about 15 grams of
crystal, which was then dissolved into diethyl ether and
subjected to a recrystallization procedure. Consequently,
15 non-colored transparent needle-shaped crystal was obtained
when L-lactic acid was used, and plated-shaped crystal was
obtained when DL-lactic acid was used.

The thus obtained crystal was developed on a
silica-gel thin layer chromatography (TLC) using a developing
20 solvent of benzene : ethyl acetate = 76:24. Spots were
shown on positions of R_f's of 0.7 to 0.8.

The acid value and ester value of the crystal were
also measured as 0 and 760 to 830, respectively.

Moreover, the nuclear magnetic resonance (NMR)
25 spectrum of the crystal was analyzed, so that methylene group
was confirmed.

Moreover, the crystal was subjected to gas - mass spectrum analysis to measure molecular weights of compounds contained in the crystal. The spectrum showed peaks confirming the presence of the compounds of the formula (1)

5 wherein " R " was CH₃ and " n " = 2-9.

(Example 2)

[The compound of formula (1) wherein " R " is CH₃ : same as the compound of formula (2)]

200 ml of L-lactic acid was charged into a four-
10 necked flask (reaction container) equipped with a thermometer, a condenser and a nitrogen inducing tube and heated in nitrogen flow at 140 °C/300 mmHg for 1 hour so that it was dehydrated. Thereafter, distilled water in the condenser was removed. The content in the container was then reacted at 140 °C/10
15 mmHg for 1 hour and subsequently at 180 °C/10 mmHg for 3 hours to obtain about 50 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction using saturated aqueous solution of sodium bicarbonate.

20 The thus obtained purified substance was dissolved into diethyl ether and recrystallized to obtain about 10 grams of non-colored transparent needle-shaped crystal.

(Example 3)

[The compound of formula (1) wherein " R " is CH₃ :
25 same as the compound of formula (2)]

100 ml of L-lactic acid was charged into the reaction

container same as Example 2 and heated in nitrogen flow at 140 °C/300 mmHg for 1 hour so that it was dehydrated. Distilled water in the condenser was then removed. The content in the container was further reacted at 140 °C/10 mmHg for 4 hours and subsequently at 180 °C/10 mmHg for 6 hours to obtain about 24 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction using saturated aqueous solution of sodium bicarbonate.

The thus obtained purified substance was dissolved into diethyl ether and recrystallized to obtain about 10 grams of non-colored transparent needle-shaped crystal.

(Example 4)

[The compound of formula (1) wherein " R " is CH₃ : same as the compound of formula (2)]

150 ml of L-lactic acid was charged into the reaction container same as Example 2 and heated in nitrogen flow at 140 °C for 2 hours gradually reducing the pressure from 760 mmHg to 30 mmHg, so that it was dehydrated. Distilled water in the condenser was then removed. The content in the container was further reacted at 140 °C/10 mmHg for 3 hours to obtain about 23 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction using saturated aqueous solution of sodium bicarbonate.

The thus obtained purified substance was dissolved

into diethyl ether and recrystallized to obtain about 10 grams of non-colored transparent needle-shaped crystal.

(Example 5)

[The compound of formula (1) wherein " R " is an alkyl group having 2 carbon atoms]

100 ml of 2-hydroxy butyric acid was charged into the reaction container same as Example 2 and heated in nitrogen flow at 140 °C for 2 hours gradually reducing the pressure from 760 mmHg to 30 mmHg, so that it was dehydrated. Distilled water in the condenser was then removed. The content of the container was further reacted at 180 °C/10 mmHg for 3 hours to obtain about 13 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction using saturated aqueous solution of sodium bicarbonate.

The thus obtained purified substance was dissolved into diethyl ether and recrystallized to obtain about 7 grams of non-colored transparent needle-shaped crystal.

(Example 6)

[The compound of formula (1) wherein " R " is CF₃]

100 ml of trifluoro lactic acid was charged into the reaction container same as Example 2 and heated in nitrogen flow at 140 °C for 2 hours gradually reducing the pressure from 760 mmHg to 10 mmHg, so that it was dehydrated. Distilled water in the condenser was then removed. The content of the container was further reacted at 180 °C/10 mmHg

for 3 hours to obtain about 16 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction
5 using saturated aqueous solution of sodium bicarbonate.

The thus obtained purified substance was dissolved into diethyl ether and recrystallized to obtain about 9 grams of non-colored transparent needle-shaped crystal.

(Example 7)

10 [The compound of formula (3)]

100 grams of glycollic acid was charged into the reaction container same as Example 2 and heated in nitrogen flow at 140 °C for 5 hours gradually reducing the pressure from 760 mmHg to 10 mmHg, so that it was reacted to obtain
15 about 20 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction using saturated aqueous solution of sodium bicarbonate.

The thus obtained purified substance was dissolved
20 into acetone and recrystallized to obtain about 12 grams of non-colored transparent plate-shaped crystal.

(Example 8)

[The compound of formula (4)]

100 ml of L-lactic acid was charged into the reaction
25 container same as Example 2 and heated in nitrogen flow at 180 - 220 °C/25 mmHg for 5 hours, so that it was dehydrated

and polycondensed to obtain about 28 grams of distillate in the condenser.

The distillate was dissolved in an appropriate amount of ethyl acetate and subjected to partition extraction using saturated aqueous solution of sodium bicarbonate.

The thus obtained purified substance was dissolved into diethyl ether and recrystallized to obtain about 15 grams of pale-yellow transparent needle-shaped crystal.

Then, polyester cyclic compound complexes, which is obtained from the OH group-containing compound and the polyester cyclic compounds of the formula (1) to (4), will be exemplified in the following examples 9 to 32 and explained in detail.

(Example 9)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of methanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and methanol.

The reaction solution was distilled under a reduced pressure to remove unreacted methanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 10)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of ethanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and ethanol.

The reaction solution was distilled under a reduced pressure to remove unreacted ethanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 11)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of propanol were charged in an air-tight

container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and propanol.

5 The reaction solution was distilled under a reduced pressure to remove unreacted propanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown
10 in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the
15 starting compounds, was confirmed by HPLC in each experiment.
(Example 12)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of butanol were charged in an air-tight container with " Teflon " packing or a glass container with
20 a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and butanol.

The reaction solution was distilled under a reduced pressure to remove unreacted butanol and purified by means
25 of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained

complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 13)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of pentanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and pentanol.

The reaction solution was distilled under a reduced pressure to remove unreacted pentanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 14)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of hexanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and hexanol.

The reaction solution was distilled under a reduced pressure to remove unreacted hexanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 15)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of heptanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and heptanol.

The reaction solution was distilled under a reduced pressure to remove unreacted heptanol and purified by means

of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

5 Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.

10 (Example 16)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of octanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to
15 obtain reaction solution containing a complex of the polyester cyclic compound and octanol.

The reaction solution was distilled under a reduced pressure to remove unreacted octanol and purified by means of an open column chromatography filled with ODS to obtain
20 about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples
25 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the

starting compounds, was confirmed by HPLC in each experiment.

(Example 17)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of nonanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and nonanol.

The reaction solution was distilled under a reduced pressure to remove unreacted nonanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.

(Example 18)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of decanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and decanol.

The reaction solution was distilled under a reduced pressure to remove unreacted decanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained
5 complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained
10 and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.
(Example 19)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of undecanol were charged in an air-tight
15 container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and undecanol.

The reaction solution was distilled under a reduced
20 pressure to remove unreacted undecanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

25 Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples

5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 20)

5 1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of dodecanol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester
10 cyclic compound and dodecanol.

 The reaction solution was distilled under a reduced pressure to remove unreacted dodecanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained
15 complex was confirmed by its characteristic peak not shown in the starting compounds.

 Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained
20 and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 21)

 1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of 2-butanol were charged in an air-tight
25 container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to

obtain reaction solution containing a complex of the polyester cyclic compound and 2-butanol.

The reaction solution was distilled under a reduced pressure to remove unreacted 2-butanol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 22)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of phenol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and phenol.

The reaction solution was distilled under a reduced pressure to remove unreacted phenol and purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 23)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of propylene glycol were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and propylene glycol.

The reaction solution was purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment. (Example 24)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of glycerin were charged in an air-tight container with " Teflon " packing or a glass container with

a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and glycerin.

5 The reaction solution was purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

10 Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed in each experiment.

(Example 25)

15 1 gram of the polyester cyclic compound obtained in Example 4 and 1 ml of lactic acid were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the
20 polyester cyclic compound and lactic acid.

The reaction solution was purified by means of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown
25 in the starting compounds.

Moreover, the above experiment was carried out using

each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.

5 (Example 26)

1 gram of the polyester cyclic compound obtained in Example 4, 1 gram of calcium lactate and 10 ml of dimethyl sulfoxide were charged in an air-tight container with "Teflon" packing or a glass container with a condenser, and
10 heated at 100 °C for more than 12 hours to obtain reaction solution containing a complex of the polyester cyclic compound and calcium lactate.

The reaction solution was distilled under a reduced pressure to remove dimethyl sulfoxide and purified by means
15 of an open column chromatography filled with ODS to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using
20 each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.
(Example 27)

25 1 gram of the polyester cyclic compound obtained in Example 4 and 1 gram of sodium 4-hydroxybutyrate were charged

in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than 12 hours to obtain reaction product containing a complex of the polyester cyclic compound and sodium 4-hydroxybutyrate.

5 The reaction product was dissolved in water and extracted with ethyl acetate to obtain about 1 ml of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

10 Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 ml of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.

15 (Example 28)

 1 gram of the polyester cyclic compound obtained in Example 4 and 1 gram of 12-hydroxydodecanoic acid were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for more than
20 12 hours to obtain reaction product containing a complex of the polyester cyclic compound and 12-hydroxydodecanoic acid.

 The reaction product was extracted with ethyl acetate to obtain about 1 g of the complex. By means of HPLC, the thus obtained complex was confirmed by its characteristic
25 peak not shown in the starting compounds.

 Moreover, the above experiment was carried out using

each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 g of the complex was obtained and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.

5 (Example 29)

1 gram of the polyester cyclic compound obtained in Example 4 and 1 gram of 16-hydroxyheptadecanoic acid were charged in an air-tight container with " Teflon " packing or a glass container with a condenser, and heated at 100 °C for
10 more than 12 hours to obtain reaction product containing a complex of the polyester cyclic compound and 16-hydroxyheptadecanoic acid.

The reaction product was extracted with ethyl acetate to obtain about 1 g of the complex. By means of HPLC,
15 the thus obtained complex was confirmed by its characteristic peak not shown in the starting compounds.

Moreover, the above experiment was carried out using each polyester cyclic compound obtained in each of Examples 5 to 8. Consequently, about 1 g of the complex was obtained
20 and its characteristic peak, which was not shown in the starting compounds, was confirmed by HPLC in each experiment.

Various properties, such as stability, of the polyester cyclic compound, the complex of the polyester cyclic compound and the bonded body of the polyester cyclic compound
25 and the ester compound, will be explained below in detail referring to examples 30 to 32.

(Example 30)

10 mg of the polyester cyclic compound of the formula (2), and the complex obtained from the compound of the formula (2) and ethanol, butanol or hexanol were charged respectively and 1 ml of distilled water was added. The thus obtained mixture was allowed to stand for 24 hours and then subjected to HPLC for evaluating the stability in water.

The polyester cyclic compound of the formula (2) was hydrolyzed 97% after 24 hours and its characteristic peak was almost disappeared. However, each characteristic peak of the complex of the compound of the formula (2) and ethanol, butanol or hexanol was not disappeared and could be 100 % confirmed after 24 hours, 72 hours, 7 days and 14 days.

As seen from this experimental results, the complex obtained from the polyester cyclic compound and the OH group-containing compound is more stable than the polyester cyclic compound itself.

(Example 31)

The polyester cyclic compound of the formula (2), and the complex obtained from the compound of the formula (2) and ethanol, butanol or hexanol were dissolved into 100 mM phosphate buffer solution (pH=6.8) respectively and then subjected to HPLC. Consequently, the characteristic peaks of the cyclic compound and the complexes were disappeared and new different peaks were appeared near column void. When each of the thus obtained solutions was extracted with ethyl

acetate and the resultant extract was subjected to HPLC again. Consequently, each characteristic peak of the cyclic compound or its complex was confirmed.

As seen from this results, the polyester cyclic
5 compound and their complexes form bonded compounds with phosphoric acid in solution of phosphoric acid.

(Example 32)

10 mg of the polyester cyclic compound of the formula
(2), and the complex obtained from the compound of the formula
10 (2) and butanol or hexanol were added to 1 ml of 10% aqueous solution of casein or carrageenan and stirred, so that agglomeration was observed.

Casein is one of proteins and has a phosphoric ester group. Carrageenan is one of polysaccharides and has a
15 sulfuric ester group. Therefore, it is assumed that the polyester cyclic compound of the formula (2) or its complex forms a bonded body with the phosphoric acid group or the sulfuric acid group and agglomerates.

In vitro experimental results will be shown below
20 in examples 33 and 34 and explained in detail, using the polyester cyclic compound of the formula (2) or (4), or the complex of the cyclic compound of the formula (2) or (4) and the OH group-containing compound.

(Example 33)

25 To a multi-plate having 24 holes seeded with Yoshida sarcoma cells in a concentration of 1×10^4 per one hole,

culture solution was charged containing the cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula (2) or (4) and butanol or hexanol. A concentration of each compound or complex in the culture solution was adjusted to 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml or 0.125 mg/ml. After the sarcoma cells were cultivated for 3 days, the number of the cells was measured. The suppression rates (%) of the compounds and complexes to control were shown in the following table.

10

TABLE 1

| Compound | suppression rate to control(%) | | | |
|------------------------------------|---------------------------------|--------|---------|----------|
| | 1 mg | 0.5 mg | 0.25 mg | 0.125 mg |
| formula (2) | 44.5 | 2.3 | 0 | 0 |
| formula (4) | 40.9 | 0 | 0 | -18.2 |
| complex of formula (2) and butanol | 74.3 | 57.5 | 28.3 | 8.8 |
| complex of formula (4) and butanol | 75.2 | 54.7 | 19.5 | 1.8 |
| complex of formula (2) and hexanol | 100 | 71.6 | 33.3 | 18.5 |
| complex of formula (4) and hexanol | 100 | 67.9 | 23.5 | 17.3 |

As seen from the above results, all the compounds of the formula (2) and (4), and the complexes obtained from the compounds reacted with butanol or hexanol suppressed the proliferation of Yoshida sarcoma cells. The suppression effect of the complexes was higher than that of the polyester cyclic compounds.

25

(Example 34)

To an MRS medium, the polyester cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula (2) or (4) and butanol, hexanol, 5 octanol or decanol was dissolved in a concentration of 0.25 mg/10 ml. Pre-cultivated lactic acid bacteria were seeded into each MRS medium in a predetermined amount. After 48 hours, it was diluted to a predetermined magnification and inoculated on an MRS agar medium to measure the number of the 10 bacteria. The multiplication rates (%) to control were shown in the following table.

TABLE 2

| Compound | Multiplication rates (%) |
|---------------------------------------|--------------------------|
| control | 0 |
| formula (2) | 15.7 |
| complex of formula (2) and butanol | 105.3 |
| complex of formula (2) and hexanol | 31.6 |
| complex of formula (2) and octanol | 31.6 |
| complex of formula (2) and decanol | 21.1 |
| formula (4) | 115.8 |
| complex of formula (4) and butanol | 15.8 |
| complex of formula (4) and hexanol | 415.8 |
| complex of formula (4) and decanol | 31.6 |

As seen from the results, all the compounds of the formula (2) and (4), and their complexes with the OH group-containing compounds improved the multiplication rates of lactic acid bacteria. The multiplication rates of the complexes were generally higher than those of the polyester cyclic compounds, although the rates varies depending on which OH group-containing compound was reacted.

Biological test results will be shown below in Examples 35 to 42 and explained in detail, using the polyester cyclic compound of the formula (2) or (4), or the complex of the polyester cyclic compound of the formula (2) or (4) and the OH group-containing compound.

(Example 35)

Yoshida sarcomas were transplanted into a Donryu-rat of an age of 5 weeks. After stabilization of the sarcoma was confirmed, the cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula (2) or (4) and butanol, hexanol, octanol or decanol was orally administered as a test sample for 2 weeks continually at a dose of 8 mg/kg/day. After the administration, sizes of the sarcomas were measured. The results were shown below.

TABLE 3

| Test group | Size of sarcoma (mm ³) | Suppression rate (%) |
|---------------------------------------|---------------------------------------|-------------------------|
| control | 7642.1 | 0 |
| formula (2) | 662.4 | 91.3 |
| complex of formula (2) and butanol | 583.0 | 92.4 |
| complex of formula (2) and hexanol | 2768.2 | 63.8 |
| complex of formula (2) and octanol | 2145.9 | 71.9 |
| complex of formula (2) and decanol | 2067.5 | 72.9 |
| formula (4) | 3216.6 | 57.9 |
| complex of formula (4) and butanol | 1023.7 | 86.6 |
| complex of formula (4) and hexanol | 3320.2 | 56.6 |
| complex of formula (4) and decanol | 3486.9 | 54.4 |

(All the values in the table were average values. Sizes of the sarcomas were indicated in mm³)

20

As seen from the above results, all of the compounds of the formula (2) and (4), and their complexes with the OH group-containing compounds showed suppression effect on the proliferation of the sarcomas. The suppression effect of the complexes were varied depending on which OH group-containing compound was reacted with the polyester cyclic

25

compound.

(Example 36)

Yoshida sarcomas were transplanted into a Donryu-rat of an age of 5 weeks. After stabilization of the sarcoma was confirmed, the cyclic compound of the formula (2), or the complex obtained from the compound of the formula (2) and butanol or hexanol was subcutaneously administered as a test sample for 2 weeks continually at a dose of 8 mg/kg/day. After the administration, sizes of the sarcomas were measured. The results were shown below.

TABLE 4

| Test group | Size of sarcoma (mm ³) | Suppression rate (%) |
|---------------------------------------|---------------------------------------|-------------------------|
| control | 9389.3 | 0 |
| formula (2) | 4320.0 | 54.0 |
| complex of formula (2) and butanol | 910.0 | 90.3 |
| complex of formula (2) and hexanol | 342.0 | 96.4 |

(All the values in the table were average values. Sizes of the sarcomas were indicated in mm³)

As seen from the above results, all of the compound of the formula (2), and its complexes with the OH group-containing compounds showed suppression effect on the

proliferation of the sarcomas. The suppression effect of the complexes was higher than that of the polyester cyclic compound. The suppression effect of the complexes was varied depending on which OH group-containing compound was
5 reacted with the polyester cyclic compound.

(Example 37)

Yoshida sarcomas were transplanted into a Donryu-rat of an age of 5 weeks. After stabilization of the sarcoma was confirmed, the polyester cyclic compound of the formula
10 (2), or the complex obtained from the compound of the formula (2) and butanol or hexanol was administered into the veins of the tail as a test sample for 10 days continually at a dose of 8 mg/kg/day. After the administration, sizes of the sarcomas were measured. The results were shown below.

15

TABLE 5

| Test group | Size of sarcoma (mm ³) | Suppression rate (%) |
|---------------------------------------|---------------------------------------|-------------------------|
| control | 5054.4 | 0 |
| formula (2) | 2960.5 | 41.4 |
| complex of formula (2) and butanol | 2386.8 | 52.8 |
| complex of formula (2) and hexanol | 324.0 | 93.6 |

(All the values in the table were average values. Sizes
25 of the sarcomas were indicated in mm³)

As seen from the above results, all of the polyester

cyclic compound of the formula (2), and its complexes with the OH group-containing compounds showed suppression effect on the proliferation of the sarcomas. The suppression effect of the complexes was higher than that of the polyester cyclic compound. The suppression effect of the complexes was varied depending on which OH group-containing compound was reacted with the polyester cyclic compound.

(Example 38)

The polyester cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula (2) or (4) and hexanol was charged in a test tube in an amount of 5 mg, 10 mg or 20 mg. 1 ml of whole blood of a rat was added into each test tube and the hemolytic effect of each compound or complex to the blood was observed. The results were shown below.

TABLE 6

| Compound/concentration | 5 mg | 10 mg | 20 mg |
|---------------------------------------|------|-------|-------|
| formula (2) | + | ++ | +++ |
| complex of formula (2) and hexanol | ++ | +++ | +++ |
| formula (4) | ± | ± | ± |
| complex of formula (4) and hexanol | ++ | +++ | +++ |

As seen from the above results, all of the polyester

cyclic compounds of the formula (2) and (4), and the complexes obtained from the cyclic compounds and the OH group-containing compound showed hemolytic effect on blood.

Considering the above results and the results of
5 Example 32, it is assumed that the cyclic compound or the complex specifically reacts with phosphoric acid groups of phospholipids on cell membranes of erythrocytes to affect the cell membranes and thereby results in hemolytic effect. In such point of view, it is considered that the complex obtained
10 by reacting a drug having an OH group or groups with the polyester cyclic compound may provide a new drug readily absorbable to a living body and having superior pharmacological action.

(Example 39)

15 The polyester cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula (2) and butanol, hexanol or glycerin was orally administered to a SD rat as a test sample for 4 weeks at a dose of 4 mg/kg/day. After the administration, liquid paraffin was administered
20 into peritoneal cavity of each rat. Three days later, peritoneal exudate cells were taken. Migration ability of macrophages produced from the peritoneal exudate cells was tested by glass capillary method. after 24 hours, a migration area of the macrophage was measured and a ratio of
25 the measured migration area to that of control group was calculated. The results were shown below.

TABLE 7

| Test group | Ratio of the migration area |
|--|-----------------------------|
| control | 1.00 |
| formula (2) | 1.73 |
| complex of formula (2) and butanol | 4.00 |
| complex of formula (2) and hexanol | 2.13 |
| complex of formula (2) and glycerin | 1.44 |
| formula (4) | 1.13 |

As seen from the results, all of the polyester cyclic compounds of the formula (2) and (4), and the complexes
15 obtained from the cyclic compound and the OH group-containing compounds improved the migration ability of macrophages of the rats. The migration ability of macrophages was more improved by the complexes than by the polyester cyclic compounds. Moreover, the migration ability of the complex
20 was varied depending on which OH group-containing compound was reacted with the cyclic compound.

(Example 40)

The polyester cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula
25 (2) and methanol, ethanol or butanol was orally administered

to a rat as a test sample for 4 weeks at a dose of 4 mg/kg/day. After the administration, content of the bowel of each rat was taken, diluted to a predetermined magnification and inoculated on an MRS agar medium to measure the number of lactic acid bacteria in the bowel. The ratios of the measured numbers to that of the control were shown in the following table.

TABLE 8

| Test group | Ratio to control |
|--|------------------|
| control | 1 |
| formula (2) | 1 |
| complex of formula (2) and methanol | 6.6 |
| complex of formula (2) and ethanol | 12.8 |
| complex of formula (2) and butanol | > 20 (★) |
| formula (4) | 3.8 |

(★) The ratio exceeded 20:upper limit of the measurement.

As seen from the results, the polyester cyclic compound of the formula (4), and the complexes obtained from the cyclic compound of the formula (2) and the OH group-

containing compounds improved the multiplication rate of lactic acid bacteria. The multiplication rates of lactic acid bacteria were more improved by the complexes than by the polyester cyclic compounds. Moreover, the multiplication rates of lactic acid bacteria were varied depending on which OH group-containing compound was reacted with the cyclic compound.

(Example 41)

The polyester cyclic compound of the formula (2), or the complex obtained from the compound of the formula (2) and butanol or hexanol was administered to a rat one time via oral or the tail vein in order to examine non effective dose. The cyclic compound of the formula (2) could not be administered into the tail vein and therefore was administered into peritoneal cavity. The results were shown below.

TABLE 9

| Administration route | Compound | Dose |
|-----------------------|------------------------------------|--------------------------|
| via oral | formula (2) | not less than 3000 mg/kg |
| | complex of formula (2) and butanol | not less than 3000 mg/kg |
| | complex of formula (2) and hexanol | not less than 3000 mg/kg |
| via tail vein | complex of formula (2) and butanol | not less than 300 mg/kg |
| | complex of formula (2) and hexanol | not less than 300 mg/kg |
| via peritoneal cavity | formula (2) | not less than 200 mg/kg |

(Example 42)

The cyclic compound of the formula (2) or (4), or the complex obtained from the compound of the formula (2) or (4) and methanol, ethanol, butanol, propylene glycol or
5 hexanol was orally administered to a SD rat as a test sample for 4 weeks continually at a dose of 4 mg/kg/day.

General physical condition of the rats was observed and the weights were measured during the oral administration, and pathologic autopsy was performed after the administration.
10 Consequently, abnormal results were not observed compared to control.

Administration tests for humans using the polyester cyclic compound of the formula (2) will be shown below in the following examples 43 to 66 and explained in detail.

15 (Example 43)

The compound of Example 3 was administered (oral administration) to a patient(10 years: male) with brain tumor at a dose of 100 mg/day. Consequently, visual problems and speech disorder, which the patient had been suffering from,
20 were improved in about one week and the reduction of the tumor was observed.

(Example 44)

The compound of Example 2 was administered (oral administration) to a patient(73 years: male) suffering from
25 prostatic malignant tumor at a dose of 60 mg/day. Consequently, subjective symptoms were improved in a few days

and the reduction of the tumors was confirmed, thereby eliminating the need for surgical operation, in about two weeks.

(Example 45)

5 The compound of Example 4 was administered (oral administration) to a patient(48 years: male) suffering from prostatic hypertrophy at a dose of 60 mg/day. Consequently, symptoms such as bleeding, difficulty of urination and residual urine were improved in two or three days.

10 (Example 46)

 The compound of Example 4 was administered (oral administration) to a patient(84 years: female) suffering from rheumatism at a dose of 60 mg/day. Consequently, symptoms such as pain and swelling, which had not been improved by the
15 other medication, were improved in about 1 month and blood test showed that rheumatoid markers were decreased.

(Example 47)

 The compound of Example 4 was administered (oral administration) to a patient(64 years: male) suffering from
20 diabetes at a dose of 200 mg/day. Consequently, subjective symptoms such as trembling of fingers were improved and his blood sugar and glycosuria were decreased in about 1 month.

(Example 48)

 The compound of Example 2 was administered (oral
25 administration) to a patient(60 years: female) suffering from breast cancer at a dose of 100 mg/day. Consequently, her

physical condition was recovered and the reduction of the cancer metastasized to the liver was confirmed in about 1 month. The administration was further continued and the cancer was almost disappeared in about 2 months.

5 (Example 49)

The compound of Example 3 was administered (oral administration) to a patient(46 years: male) suffering from gastric cancer at a dose of 100 mg/day. Consequently, his physical condition was recovered in about 1 month and
10 metastatic focus was disappeared in about 2 months. Primary focus was also cured.

(Example 50)

The compound of Example 3 was administered (oral administration) to a patient(66 years: male) suffering from
15 lung cancer at a dose of 100 mg/day. Consequently, the reduction of the focus was confirmed in about 2 months.

(Example 51)

The compound of Example 3 was administered (oral administration) to a patient(40 years: male) suffering from
20 pharyngeal cancer at a dose of 100 mg/day. Consequently, his physical condition was improved and the number of leukocytes was recovered to a normal value in about 1 month. Thereafter, the reduction of the cancer and the falling-out of the tumor tissue from pharynx were observed.

25 (Example 52)

The compound of Example 4 was administered (oral

administration) to a patient(32 years: female) suffering from allergic rhinitis and pollen allergy at a dose of 20 mg/day. Consequently, these symptoms were disappeared which had been relieved but not disappeared by administering commercial
5 drugs.

(Example 53)

The compound of Example 4 was administered (oral administration) to a patient(44 years: male) suffering from hepatic insufficiency at a dose of 60 mg/day. Consequently,
10 values of blood test were recovered to normal values, his physical condition was improved and the other measured values were also improved in about two weeks.

(Example 54)

The compound of Example 4 was administered (oral
15 administration) to a patient(53 years: female) suffering from parkinson disease at a dose of 100 mg/day. Consequently, her physical condition, exercise function and muscular strength were improved, so that she became able to live daily life without particular difficulties.

20 (Example 55)

The compound of Example 4 was administered (oral administration) to a patient(45 years: female) suffering from collagen disease at a dose of 100 mg/day. Consequently, her ache or pain was disappeared in two or three days and
25 administration of an analgesic obtained from a doctor was stopped.

(Example 56)

The compound of Example 4 was administered (oral administration) to a patient(46 years: male) suffering from bronchial asthma at a dose of 60 mg/day. Consequently, cough
5 and phlegm were decreased to eliminate the need for a medicine of inhalation.

(Example 57)

The compound of Example 4 was administered (oral administration) to a patient(40 years: female) suffering from
10 Meniere syndrome at a dose of 100 mg/day. Consequently, her subjective symptoms were relieved in two or three days. After continuing the administration, the symptoms of the syndrome were disappeared.

(Example 58)

15 The compound of Example 4 was administered (oral administration) to a patient(58 years: female) suffering from hypertension at a dose of 30 mg/day. Consequently, the blood pressure was decreased to a value near normal values in about 1 month.

20 (Example 59)

The compound of Example 4 was administered (oral administration) to a patient(50 years: female) having shoulder tension and a cold constitution at a dose of 30 mg/day. Consequently, each symptom was clearly improved in about two
25 weeks, eliminating the need for instruments such as warm keeper which had been used.

(Example 60)

The compound of Example 4 was administered (oral administration) to a patient(40 years: male) suffering from chronic fatigue at a dose of 30 mg/day. Consequently, he
5 became free from the fatigue and hangover after drinking in about one week.

(Example 61)

The compound of Example 4 was administered (oral administration) to a patient(34 years: female) suffering from
10 constipation at a dose of 30 mg/day. Consequently, her bowel movement was activated and evacuation was normalized in about 1 or 2 days.

(Example 62)

The compound of Example 4 was administered (oral
15 administration) to a patient(14 years: male) having a lot of pimples at a dose of 30 mg/day. Consequently, his skin became smoother in about two weeks.

(Example 63)

The compound of Example 4 was administered (oral
20 administration) to a patient(34 years: female) suffering from severe menstrual pain at a dose of 30 mg/day. Consequently, low back pain and nausea caused by the menstrual pain were relieved which had not been improved by commercial drugs, and the symptoms were improved, so that she became able to live
25 daily life without particular difficulties.

(Example 64)

A patient(60 years: female) suffering from skin cracks and chaps applied, onto the affected parts, solution of 60 mg of the compound of Example 4 dissolved into 5 - 6 ml of water. Consequently, the above symptoms were improved in 1 to 3 days.

(Example 65)

A patient(5 years: female) suffering from severe atopic dermatitis applied, onto the affected parts, commercial ointment containing the compound of Example 4 in a concentration of 5 %. Consequently, the symptoms were improved in about 1 - 2 weeks.

(Example 66)

A patient(34 years: female) suffering from severe corns with pain applied, onto the affected parts, commercial hand cream containing the compound of Example 4 in a concentration of 5 %. Consequently, the pain was relieved in 1 - 2 days and the symptoms were improved in 2 - 3 weeks.

Industrial Applicability :

20

As described above, the polyester cyclic compound and the complex of the polyester cyclic compound of the invention demonstrate many pharmacological effects such as carcinostatic effect and immunological regulation specifically to a living body. Moreover, by the effect of the OH group-containing compound, the polyester cyclic

25


compound may be easily absorbed into a living body so that the pharmacological effects are further improved. Moreover, the polyester cyclic compound hardly demonstrates any toxicity. Therefore, by administering the cyclic compound or the complex to human, the compound and the complex is particularly effective to medication or prevention of cancer, rheumatism, prostic disease, dementia, chronic hepatitis, autoimmune disease, allergic disease, menopausal syndrome, menstrual pain or adult diseases such as diabetes and hypertension. The compound or the complex is also effective to medication or prevention of diseases of animals.

Moreover, the polyester cyclic compound has properties to form a complex with an OH group-containing compound and to form a bonded body with a compound having ester groups such as a phosphoric group or sulfuric group or the like. Therefore, the polyester cyclic compound may be reacted with a drug having an OH group or a ester group and thereby development of a novel drug and novel reagent is expected. Moreover, the compound, the complex or the bonded body is expected to be used as a catalyst during a synthetic reaction process.

CLAIMES

1. A polyester cyclic compound represented by the following formula (1).


5



10 (in the formula (1), each "R" is independently hydrogen atom, an alkyl group having 1 - 5 carbon atoms, or an alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom, and "n" is an integer of 2 to 9.)

15

2. A polyester cyclic compound represented by the following formula (2).



20


(in the formula (2), "n" is an integer of 2 to 9.)

25


3. A complex of at least one compound containing an OH group or groups therein and at least one polyester cyclic

compound selected from a group consisting of a compound represented by the following formula (1), a compound represented by the following formula (3) and a compound represented by the following formula (4).


5



10



15




(in the formulas, each "R" is independently hydrogen atom, an alkyl group having 1 - 5 carbon atoms, or an alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom, and "n" is an integer of 2 to 9.).

25


4. The complex as claimed in claim 3, wherein the

compound containing an OH group or groups is selected from a group consisting of an organic compound having an alcoholic hydroxyl group or phenolic hydroxyl group and a hydroxy acid.


- 5 5. A bonded body obtained by bonding at least one ester compound and at least one polyester cyclic compound selected from a group consisting of a compound represented by the following formula (1), a compound represented by the following formula (3) and a compound represented by the following formula (4).
- 10



15



20





25


(in the formulas, each " R " is independently hydrogen atom,

an alkyl group having 1 - 5 carbon atoms, or an alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom, and " n " is an integer of 2 to 9.), or by bonding at least one ester compound and at least one complex of said polyester cyclic compound and a compound containing an OH group or groups therein.

6. The bonded body as claimed in the claim 5 wherein the ester compound is selected from a group consisting of a phosphoric ester, a sulfuric ester and a carbonic ester.

7. A medical or pharmaceutical composition containing, as its effective component, at least one polyester cyclic compound selected from a group consisting of a compound represented by the following formula (1), a compound represented by the following formula (3) and a compound represented by the following formula (4).





(in the formulas, each " R " is independently hydrogen atom, an alkyl group having 1 - 5 carbon atoms, or an alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom, and " n " is an integer of 2 to 9.), or at least one complex of the polyester cyclic compound and a compound containing an OH group or OH groups therein, or at least one bonded body obtained by bonding an ester compound and the polyester cyclic compound or the complex.


8. The medical or pharmaceutical composition as claimed in claim 7 applied to medication or prevention of cancer, rheumatism, prostic diseases, dementia, chronic hepatitis, autoimmune disease, allergic diseases, menopausal syndrome, menstrual pain or adult diseases such as diabetes and hypertension.

AMENDED CLAIMS

[received by the International Bureau on 10 June 1997 (10.06.97) ;
original claim 1 amended; remaining claims unchanged (2 pages)]


1. (amended) A polyester cyclic compound represented
by the following formula (6).

5



10 (in the formula (6), each "R" is independently hydrogen atom,
an alkyl group having 1 - 5 carbon atoms, or an alkyl group
having 1 - 5 carbon atoms wherein one or more hydrogen atom
is replaced by a fluorine atom, and at least one of "R" is
the alkyl group having 1 - 5 carbon atoms, or the alkyl group
15 having 1 - 5 carbon atoms wherein one or more hydrogen atom
is replaced by a fluorine atom. "n" is an integer of 2
to 9.)

2. A polyester cyclic compound represented by the
20 following formula (2).



25

(in the formula (2), "n" is an integer of 2 to 9.)

3. A complex of at least one compound containing an
OH group or groups therein and at least one polyester cyclic

5

10

15

20

25

STATEMENT UNDER ARTICLE 19

The formula (6) recited in the amended claim 1 is restricted within a scope in which at least one of "R" in the repeating units thereof is the alkyl group having 1 - 5 carbon atoms, or the alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom.

On the other hand, the cyclic oligo esters of glycolic acid disclosed in ACTA CHEM. SCAND. SER.B, Vol.B32, no.4, 1978, pages 306-307 do not contain any repeating units having the alkyl group having 1 - 5 carbon atoms, or the alkyl group having 1 - 5 carbon atoms wherein one or more hydrogen atom is replaced by a fluorine atom.

INTERNATIONAL SEARCH REPORT

In: tional Application No
PCT/JP 97/00353

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D323/00 A61K31/335

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | CHEMICAL ABSTRACTS, vol. 89, no. 13, 1978 Columbus, Ohio, US; abstract no. 108036t, J.DALE ET AL.: "CYCLIC OLIGOESTERS OF GLYCOLIC ACID." page 790; column 2; XP002028628 see abstract | 1 |
| X | & ACTA CHEM. SCAND. SER.B, vol. B32, no. 4, 1978, SWEDEN, pages 306-307, | 1 |
| A | EP 0 522 422 A (MITSUBISHI KASEI) 13 January 1993 see page 1 - page 7 | 1 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

2 April 1997

Date of mailing of the international search report

0 9. 04. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

(Int'l) Application No

PCT/JP 97/00353

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP 522422 A | 13-01-93 | JP 5009186 A | 19-01-93 |
| | | JP 5009185 A | 19-01-93 |
| | | JP 5009272 A | 19-01-93 |
| | | US 5286842 A | 15-02-94 |
| ----- | | | |